6 results
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
To study the effect of acetazolamide on lithium-induced NDI.
The primary objective of this study is to evaluate the effectiveness of two differently sized pistons used in primary stapedotomy for otosclerosis in terms of hearing improvement, complication rate and general and disease-specific quality of life.
The primary objective will be to assess whether cerebrovascular reactivity is impaired in patients with steno-occlusive disease of the vertebrobasilar artery .
1. What is the effect of a clinical oral dose of acetazolamide on the isocapnic hypoxic response (IHR), i.e. an exposure to hypoxia (end-tidal PO2 ~ 5.8 kPa) during 30 min? Does the agent increase the IHR as would be expected from the state of…
In a phase II study we will evaluate safety and proof-of-concept of acetazolamide in patients with aneurysmal SAH. The primary aim of this study is to evaluate whether acetazolamide improves cerebral perfusion as measured with magnetic resonance…